CP
LGND icon

CenterBook Partners’s Ligand Pharmaceuticals LGND Stock Holding History

CenterBook Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,434
Closed -$1.14M – 628
2025
Q3 		$1.14M Sell
6,434
-7,033
-52% -$1.05M 0.06% 353
2025
Q2 		$1.53M Sell
13,467
-54,832
-80% -$5.86M 0.09% 265
2025
Q1 		$7.18M Buy
68,299
+44,760
+190% +$5.06M 0.46% 58
2024
Q4 		$2.52M Sell
23,539
-27,437
-54% -$3.1M 0.15% 171
2024
Q3 		$5.1M Sell
50,976
-2,403
-5% -$242K 0.31% 94
2024
Q2 		$4.5M Buy
53,379
+20,749
+64% +$1.65M 0.28% 132
2024
Q1 		$2.39M Buy
+32,630
New +$2.41M 0.16% 214

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

CenterBook Partners's LGND Position: Q4 2025 in Review

CenterBook Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 6,434 shares — an estimated $1.14M sold.

CenterBook Partners first reported a position in LGND in Q1 2024 and held it in 7 quarters. The position peaked at $7.18M in Q1 2025. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • CenterBook Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • CenterBook Partners sold 6,434 Ligand Pharmaceuticals shares in Q4 2025, an estimated $1.14M.
  • CenterBook Partners first reported a position in Ligand Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • CenterBook Partners's Ligand Pharmaceuticals position peaked at $7.18M in Q1 2025.
  • 350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on CenterBook Partners's 13F filing for Q4 2025, filed 11 Feb 2026.